TESTING -ON Post-Trial ObservatioNal Cohort Study

Launched by THE GEORGE INSTITUTE · Jun 21, 2022

Keywords

ClinConnect Summary

The TESTING -ON study is looking at the long-term effects of a medication called oral methylprednisolone on patients with certain kidney diseases, including IgA Nephropathy and End Stage Kidney Disease (ESKD). This study is important because it will help researchers understand how different doses of the medication, and factors like ethnicity and kidney function, can affect patients over time. The trial is currently recruiting participants who were part of the earlier TESTING trial, specifically those who did not experience kidney failure, death, or withdraw their consent during that study.

If you or a loved one is interested in participating, you should be between the ages of 65 and 74 or between 36 and 524 years old, and you must have been part of the previous TESTING trial. Participants in this study can expect to contribute to valuable research that could improve treatment options for kidney diseases in the future. It’s a great opportunity to help others while also learning more about your own health and treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1) Only participants who were randomised into the TESTING trial
• • Exclusion Criteria
• • 1. Participants who have reached kidney failure requiring maintenance dialysis or kidney transplantation during the TESTING trial
• • 2. Participants who died during the TESTING trial
• • 3. Participants who had withdrawn their consent during the TESTING trial
• • 4. Participants who are unable to provide consent for some other reason